{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:12:14Z","timestamp":1787879534416,"version":"build-2784847793"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13555-025-01339-9","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T05:40:38Z","timestamp":1737610838000},"page":"323-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Federico","family":"Diotallevi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Stingeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Feliciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"Legori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Argenziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Cozzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bellinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bianchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Marco","family":"D\u2019Agostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Matacchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-0839","authenticated-orcid":false,"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"1339_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team Global Epidemiology of Psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377\u201385. https:\/\/doi.org\/10.1038\/jid.2012.339.","journal-title":"J Invest Dermatol"},{"key":"1339_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/PPA.S39887","volume":"7","author":"C Lewis-Beck","year":"2013","unstructured":"Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199\u2013205. https:\/\/doi.org\/10.2147\/PPA.S39887.","journal-title":"Patient Prefer Adherence"},{"key":"1339_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ced.12805","volume":"41","author":"JF Merola","year":"2016","unstructured":"Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41:486\u20139. https:\/\/doi.org\/10.1111\/ced.12805.","journal-title":"Clin Exp Dermatol"},{"key":"1339_CR4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jaad.2008.11.890","volume":"60","author":"CS Chan","year":"2009","unstructured":"Chan CS, Voorhees ASV, Lebwohl MG, Korman NJ, Young M, Bebo BF, Kalb RE, Hsu S. Treatment of severe scalp psoriasis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2009;60:962\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2008.11.890.","journal-title":"J Am Acad Dermatol"},{"key":"1339_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/bjd.17147","volume":"180","author":"M Larsabal","year":"2019","unstructured":"Larsabal M, Ly S, Sbidian E, Moyal-Barracco M, Dauendorffer JN, Dupin N, Richard MA, Chosidow O, Beylot-Barry M. GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis. Br J Dermatol. 2019;180:647\u201356. https:\/\/doi.org\/10.1111\/bjd.17147.","journal-title":"Br J Dermatol"},{"key":"1339_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12895-020-00099-7","volume":"20","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20:3. https:\/\/doi.org\/10.1186\/s12895-020-00099-7.","journal-title":"BMC Dermatol"},{"key":"1339_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bjd.17403","volume":"181","author":"M Augustin","year":"2019","unstructured":"Augustin M, Sommer R, Kirsten N, Danckworth A, Radtke MA, Reich K, Thaci D, Boehncke WH, Langenbruch A, Mrowietz U. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181:358\u201365. https:\/\/doi.org\/10.1111\/bjd.17403.","journal-title":"Br J Dermatol"},{"key":"1339_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clindermatol.2016.09.004","volume":"35","author":"B Engin","year":"2017","unstructured":"Engin B, A\u015fk\u0131n \u00d6, T\u00fcz\u00fcn Y. Palmoplantar psoriasis. Clin Dermatol. 2017;35:19\u201327. https:\/\/doi.org\/10.1016\/j.clindermatol.2016.09.004.","journal-title":"Clin Dermatol"},{"key":"1339_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2005.07.073","volume":"57","author":"MM Jiaravuthisan","year":"2007","unstructured":"Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57:1\u201327. https:\/\/doi.org\/10.1016\/j.jaad.2005.07.073.","journal-title":"J Am Acad Dermatol"},{"key":"1339_CR10","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1080\/09546634.2018.1453125","volume":"29","author":"KAP Meeuwis","year":"2018","unstructured":"Meeuwis KAP, Potts Bleakman A, Van De Kerkhof PCM, Dutronc Y, Henneges C, Kornberg LJ, Menter A. Prevalence of genital psoriasis in patients with psoriasis. J Dermatol Treat. 2018;29:754\u201360. https:\/\/doi.org\/10.1080\/09546634.2018.1453125.","journal-title":"J Dermatol Treat"},{"key":"1339_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40257-016-0191-7","volume":"17","author":"I Raposo","year":"2016","unstructured":"Raposo I, Torres T. Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol. 2016;17:349\u201358. https:\/\/doi.org\/10.1007\/s40257-016-0191-7.","journal-title":"Am J Clin Dermatol"},{"key":"1339_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamadermatol.2018.0793","volume":"154","author":"P Foley","year":"2018","unstructured":"Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A. Efficacy of Guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. JAMA Dermatol. 2018;154:676\u201383. https:\/\/doi.org\/10.1001\/jamadermatol.2018.0793.","journal-title":"JAMA Dermatol"},{"key":"1339_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/jdv.12553","volume":"29","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015;29:353\u201360. https:\/\/doi.org\/10.1111\/jdv.12553.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1339_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","volume":"78","author":"BE Elewski","year":"2018","unstructured":"Elewski BE, Okun MM, Papp K, Baker CS, Crowley JJ, Guillet G, Sundaram M, Poulin Y, Gu Y, Geng Z, et al. Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol. 2018;78:90\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2017.08.029.","journal-title":"J Am Acad Dermatol"},{"key":"1339_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s13555-020-00383-x","volume":"10","author":"N Wasel","year":"2020","unstructured":"Wasel N, Tha\u00e7i D, French LE, Conrad C, Dutronc Y, Gallo G, Berggren L, Lacour JP. Ixekizumab and Ustekinumab efficacy in nail psoriasis in patients with moderate-to-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S) Dermatol. Ther. 2020;10:663\u201370. https:\/\/doi.org\/10.1007\/s13555-020-00383-x.","journal-title":"Ther"},{"key":"1339_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.10.534","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Reich K, Shu L, Guzzo C. Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: results from controlled clinical trials. J Am Acad Dermatol. 2008;58: AB120. https:\/\/doi.org\/10.1016\/j.jaad.2007.10.534.","journal-title":"J Am Acad Dermatol"},{"key":"1339_CR17","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature14175","volume":"521","author":"T Kopp","year":"2015","unstructured":"Kopp T, Riedl E, Bangert C, Bowman E, Greisenegger EK, Horowitz A, Kittler H, Blumenschein W, Mcclanahan T, Marbury T, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015;521:222\u20136. https:\/\/doi.org\/10.1038\/nature14175.","journal-title":"Nature"},{"key":"1339_CR18","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/bjd.13932","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Tha\u00e7i D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173:930\u20139. https:\/\/doi.org\/10.1111\/bjd.13932.","journal-title":"Br J Dermatol"},{"key":"1339_CR19","unstructured":"Ilumetri, SmPC. [(accessed on 30 June 2024)]. Available online:\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ilumetri-epar-product-information_it.pdf"},{"key":"1339_CR20","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/09546634.2019.1640348","volume":"31","author":"B Elewski","year":"2020","unstructured":"Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, Rozzo S, Mendelsohn AM, Parno J, Gordon K. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. J Dermatol Treat. 2020;31:763\u20138.","journal-title":"J Dermatol Treat"},{"key":"1339_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Tha\u00e7i D, Nograles K, Mehta A, Cichanowitz N, Li Q, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (ReSURFACE 1 and ReSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(17)31279-5.","journal-title":"Lancet"},{"key":"1339_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.7573\/dic.2021-2-6","volume":"10","author":"M Burlando","year":"2021","unstructured":"Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:2\u20136. https:\/\/doi.org\/10.7573\/dic.2021-2-6.","journal-title":"Drugs Context"},{"key":"1339_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000519924","volume":"12","author":"KA Drerup","year":"2021","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-il-23p19 biologic tildrakizumab: Results of a real-world prospective cohort study in nonselected patients. Dermatology. 2021;12:1\u20135. https:\/\/doi.org\/10.1159\/000519924.","journal-title":"Dermatology"},{"issue":"9","key":"1339_CR24","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1111\/ijd.15840","volume":"61","author":"M Gal\u00e1n-Gutierrez","year":"2022","unstructured":"Gal\u00e1n-Gutierrez M, Rodriguez-Fernandez Freire L, Ruiz-Villaverde R. Tildrakizumab: short-term efficacy and safety in real clinical practice. Int J Dermatol. 2022;61(9):e355\u20137. https:\/\/doi.org\/10.1111\/ijd.15840.","journal-title":"Int J Dermatol"},{"issue":"16","key":"1339_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2147\/CCID.S402183","volume":"27","author":"A Ruggiero","year":"2023","unstructured":"Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Investig Dermatol. 2023;27(16):529\u201336. https:\/\/doi.org\/10.2147\/CCID.S402183.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"1339_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15488","author":"G Caldarola","year":"2022","unstructured":"Caldarola G, Galluzzo M, Bernardini N, Calabrese L, Grimaldi M, Moretta G, Pagnanelli G, Shumak RG, Talamonti M, Tofani L, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022. https:\/\/doi.org\/10.1111\/dth.15488.","journal-title":"Dermatol Ther"},{"issue":"17","key":"1339_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.2147\/CCID.S464326","volume":"7","author":"M Megna","year":"2024","unstructured":"Megna M, Ruggiero A, Tommasino N, Brescia C, Martora F, Cacciapuoti S, Potestio L. Effectiveness and safety of tildrakizumab in psoriasis patients who failed anti-IL17 treatment: a 28-week real-life study. Clin Cosmet Investig Dermatol. 2024;7(17):1037\u201342.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"1339_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40257-016-0191-7","volume":"17","author":"I Raposo","year":"2016","unstructured":"Raposo I, Torres T. Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol. 2016;17(4):349\u201358.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1339_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clindermatol.2016.09.004","volume":"35","author":"B Engin","year":"2017","unstructured":"Engin B, A\u015fk\u0131n \u00d6, T\u00fcz\u00fcn Y. Palmoplantar psoriasis. Clin Dermatol. 2017;35(1):19\u201327.","journal-title":"Clin Dermatol"},{"issue":"6","key":"1339_CR30","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Tommasino N, Potestio L, Battista T, Ruggiero A, Noto M, Fabbrocini G, Genco L. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813\u201320. https:\/\/doi.org\/10.1080\/09546634.2022.2081655. (Epub 2022 May 29).","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"1339_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s13555-017-0207-0","volume":"7","author":"IM Sanchez","year":"2017","unstructured":"Sanchez IM, Sorenson E, Levin E, Liao W. The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review. Dermatol Ther (Heidelb). 2017;7(4):425\u201346. https:\/\/doi.org\/10.1007\/s13555-017-0207-0. (Epub 2017 Nov 15).","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1339_CR32","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1365-2133.2010.09897.x","volume":"163","author":"S Gerdes","year":"2010","unstructured":"Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol. 2010;163(5):1116\u20138.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1339_CR33","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jdv.14237","volume":"31","author":"A Menter","year":"2017","unstructured":"Menter A, Warren RB, Langley RG, Merola JF, Kerr LN, Dennehy EB, Shrom D, Amato D, Okubo Y, Reich K. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31(10):1686\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1339_CR34","unstructured":"Gottlieb ASJ, Dorn VM. Secukinumab efficacy and safety in subjects with moderate to severe palmoplantar psoriasis in a phase 3b study (GESTURE). 23rd World Congress of Dermatology; Vancouver, 2015; pp. 8\u201313."},{"key":"1339_CR35","doi-asserted-by":"crossref","unstructured":"Reich K. Impact of ixekizumab on palmoplantar plaque psoriasis compared to placebo and etanercept: results from UNCOVER-2. In: 74th Annual Meeting of the American Academy of Dermatology; Washington, DC, 2016.","DOI":"10.1016\/j.jaad.2016.02.984"},{"key":"1339_CR36","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/09546634.2019.1640348","volume":"31","author":"B Elewski","year":"2020","unstructured":"Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, Rozzo S, Mendelsohn AM, Parno J, Gordon K. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. J Dermatol Treat. 2020;31:763\u20138. https:\/\/doi.org\/10.1080\/09546634.2019.1640348.","journal-title":"J Dermatol Treat"},{"key":"1339_CR37","first-page":"2","volume":"10","author":"M Burlando","year":"2021","unstructured":"Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:2\u20136.","journal-title":"Drugs Context"},{"key":"1339_CR38","first-page":"1","volume":"12","author":"KA Drerup","year":"2021","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-il-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2021;12:1\u20135.","journal-title":"Dermatology"},{"issue":"9","key":"1339_CR39","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.3390\/jcm11092631","volume":"11","author":"M Galluzzo","year":"2022","unstructured":"Galluzzo M, Talamonti M, Cioni A, Maffei V, Shumak RG, Tofani L, Bianchi L, Campione E. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022;11(9):2631. https:\/\/doi.org\/10.3390\/jcm11092631.","journal-title":"J Clin Med"},{"key":"1339_CR40","doi-asserted-by":"publisher","DOI":"10.23880\/cdoaj-16000299","author":"C Ariasi","year":"2023","unstructured":"Ariasi C, Licata G, Romano C, Bettolini L, Mezzana S, Maione V, Calzavara-Pinton PG, Arisi MC. A real-life study on the use of tildrakizumab in psoriatic patients. Clin Dermatol Open Access J. 2023. https:\/\/doi.org\/10.23880\/cdoaj-16000299.","journal-title":"Clin Dermatol Open Access J"},{"issue":"1","key":"1339_CR41","doi-asserted-by":"publisher","first-page":"2319304","DOI":"10.1080\/09546634.2024.2319304","volume":"35","author":"D Orsini","year":"2024","unstructured":"Orsini D, Caldarola G, Dattola A, Campione E, Bernardini N, Frascione P, De Simone C, Richetta AG, Galluzzo M, Skroza N, Assorgi C, Amore E, Falco GM, Gaeta Shumak R, Artosi F, Maretti G, Potenza C, Bianchi L, Pellacani G, Peris K, Bonifati C, Graceffa D. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study). J Dermatolog Treat. 2024;35(1):2319304. https:\/\/doi.org\/10.1080\/09546634.2024.2319304. (Epub 2024 Feb 27. PMID: 38413097).","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"1339_CR42","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/jdv.12272","volume":"28","author":"R Bissonnette","year":"2014","unstructured":"Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol. 2014;28(10):1298\u2013305. https:\/\/doi.org\/10.1111\/jdv.12272.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1339_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jdermsci.2016.09.019)","volume":"85","author":"R Bissonnette","year":"2017","unstructured":"Bissonnette R, Fuentes-Duculan J, Mashiko S, et al. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. J Dermatol Sci. 2017;85(1):20\u20136. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.09.019).","journal-title":"J Dermatol Sci"},{"key":"1339_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jdin.2024.09.001","volume":"18","author":"D Wilsmann-Theis","year":"2024","unstructured":"Wilsmann-Theis D, Patt S, Pinter A, et al. Efficacy and safety of guselkumab in European patients with palmoplantar pustulosis: a multi-center, single-arm clinical trial (GAP study). JAAD Int. 2024;18:69\u201378. https:\/\/doi.org\/10.1016\/j.jdin.2024.09.001. (Published 2024 Oct 2).","journal-title":"JAAD Int"},{"key":"1339_CR45","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1302a97","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Vignoli CA, Pavia G, Narcisi A, Costanzo A, Perugini C. Risankizumab for the treatment of palmoplantar pustular psoriasis: a report of two cases. Dermatol Pract Concept. 2023. https:\/\/doi.org\/10.5826\/dpc.1302a97. (Published online April 1).","journal-title":"Dermatol Pract Concept."},{"issue":"4","key":"1339_CR46","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3390\/jcm12041662","volume":"12","author":"G Avallone","year":"2023","unstructured":"Avallone G, Maronese CA, Murgia G, et al. Interleukin-17 vs. Interleukin-23 inhibitors in pustular and erythrodermic psoriasis: a retrospective, multicentre cohort study. J Clin Med. 2023;12(4):1662. https:\/\/doi.org\/10.3390\/jcm12041662. (Published 2023 Feb 19).","journal-title":"J Clin Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01339-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01339-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01339-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:10:46Z","timestamp":1739837446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01339-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01339-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Campanati has served as consultant\/advisor, received speaker honoraria and\/or grants, and\/or is investigator Abbvie, Galderma, Celgene, Janssen-Cilag, Leo-pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, UCB, Almirall, Sanofi-Aventis, Boehringer-Ingelheim, Bristol Myers Squibb, Incyte; M Burlando has acted as speaker or advisory board member for Abbvie, Amgen, Leo-pharma, Eli Lilly, Novartis, UCB, Almirall; E. Cozzani has acted as speaker or advisory board member for Abbvie, Amgen, Leo-pharma, Eli Lilly, Novartis, UCB, Almirall; K. Hansel has acted as investigator and speaker for Abbvie, Almirall, Amgen, Novartis, and Sanofi; L. Stingeni has acted as investigator and speaker for Abbvie, Almirall, Amgen, Leo Pharma, Lilly, Novartis, Pfizer, and Sanofi; L. Bianchi has acted as speaker or advisory board member for Abbvie, Leo-Pharma, Eli Lilly, Novartis, Pfizer, UCB, Almirall, Sanofi-Aventis, Biogen, Bristol, Boehringer, Johnson & Johnson; M. Galluzzo acted as a speaker and\/or consultant for AbbVie, Almirall, Eli-Lilly, Johnson & Johnson, LeoPharma, Novartis, and Sanofi; he has participated in clinical trials for AbbVie, Almirall, Boehringer-Ingelheim, Eli-Lilly, Incyte, Johnson & Johnson, Leo Pharma, Novartis and Sanofi.; M. Esposito has served as consultant\/speaker from Abbvie, Amgen, Eli Lilly, Janssen, Leo Pharma, Novartis, UCB, Sanofi\/Regeneron; MC Fargnoli has served as consultant\/advisor, received speaker honoraria and\/or grants, and\/or is investigator for AMGEN, Almirall, Abbvie, Boehringer-Ingelheim, BMS, Galderma, Kyowa Kyrin, Incyte, LEO Pharma, Pierre Fabre, UCB, Lilly, Pfizer, Janssen, MSD, Novartis, Sanofi, Regeneron, Sun Pharma, Takeda; M. Megna has acted as a speaker or consultant for Abbvie, Amgen, Almirall, BMS, Boehringer, Leo-pharma, Eli Lilly, Janssen, Novartis, UCB; A. Balato has acted as speaker or advisory board member for Abbvie, Amgen, Almirall, BMS, Boehringer, Leo-pharma, Eli Lilly, Novartis, Pfizer, UCB, Sanofi. Federico Diotallevi, Pietro Quaglino, Luca Mastorino, Claudio Feliciani, Lucia Gallo, Agostina Legori, Giuseppe Argenziano, Federico Bardazzi, Paolo Gisondi, Francesco Bellinato, Tommaso Bianchelli, Giovanni Marco D\u2019Agostino, Giulia Matacchione have no conflict of interest to declare. Anna Campanati is an Editorial Board member Dermatology and Therapy. Anna Campanati was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. All authors read and approved the final version of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The patients in this manuscript have given written informed consent to publication of their case details. IRB approval was waived, the study was conducted respecting the Declaration of Helsinki, and all patients signed an informed consent before starting the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}